Mitochondrial DNA Variants in a Portuguese Population of Patients with Alzheimer’s Disease

Manuela Grazina\textsuperscript{a,b} Filipe Silva\textsuperscript{b,c} Isabel Santana\textsuperscript{c} João Pratas\textsuperscript{b} Beatriz Santiago\textsuperscript{c} Miguel Oliveira\textsuperscript{b} Isabel Carreira\textsuperscript{a} Luís Cunha\textsuperscript{b,c} Catarina Oliveira\textsuperscript{a-c}

\textsuperscript{a}Faculty of Medicine, University of Coimbra, \textsuperscript{b}Center for Neurosciences of Coimbra and \textsuperscript{c}Neurological Unit, University Hospital of Coimbra, Coimbra, Portugal

Introduction

In the last few years, some evidence has been found for energy metabolism deficiency and mitochondrial DNA (mtDNA) alterations contributing to the etiopathogenesis of Alzheimer’s disease (AD). In 1992, Lin et al. \cite{1} identified, in AD patients, a G-A transition and a G-T transversion, both at nucleotide 5460 of mtDNA NADH dehydrogenase subunit 2 gene, but these findings were not confirmed \cite{2}. Later, Shoffner et al. \cite{3} reported four polymorphisms (nucleotides 3196, 3397, 4336 and 956–965 insertion), having special importance, and the tRNA (Gln) variant at position 4336 that modifies a moderately conserved nucleotide. Kösel et al. \cite{4} found in patients with Parkinson’s disease (PD) a known missense mutation at nucleotide 3338 of the NADH dehydrogenase subunit 1 (ND1) mtDNA gene that changes the amino acid valine to alanine. This mutation has previously been described by Chalmers et al. \cite{5} in a control subject, and it was absent in subsets of our PD \cite{6} and frontotemporal dementia \cite{7} patients.

We analyzed mtDNA ND1 nucleotides 3337–3340 in 129 AD patients and 125 healthy age-matched control subjects, in order to determine if mtDNA ND1 is related to AD. We also tried to find an additional peripheral genetic risk factor for the disease.
Methods

One hundred and twenty-nine Caucasian patients (80 female and 49 male; mean age: 69.6 ± 8.9 years, range: 41–89 years; mean age at onset of AD: 65.5 ± 9.3 years, range: 35–86 years) with the diagnosis of probable AD, as defined by standard criteria [8, 9] and followed at the Neurological Unit of the University Hospital of Coimbra, were randomly selected for this study. The patients had at least 1-year history of cognitive decline confirmed by neuropsychological assessment, and positive family history was reported in 40 patients (31%). Family history was considered positive when a first degree relative had dementia. Early onset AD was considered when the patient started the disease course before reaching the age of 65 years. Global cognitive impairment was quantified using the Mini-Mental State Examination (MMSE) [10]. The mean MMSE score was 12.1 ± 7.9 (range 0–29) and global dementia severity was staged in accordance with the Clinical Dementia Rating (CDR) [11, 12] where CDR 0 indicates no impairment and CDR 0.5, 1, 2 and 3 indicate questionable, mild, moderate and severe dementia, respectively. Our patient group included 35 patients with CDR 1, 55 with CDR 2 and 39 with CDR 3. One hundred and twenty-five healthy age-matched Caucasian control subjects, free of neurological disorders (73 female and 52 male; mean age: 65.2 ± 13.0 years, range: 37–90 years) were recruited among the staff and accompanying persons of the patients. Informed consent was obtained from all patients and controls, according to the University Hospital Ethical Council guidelines. Total cellular DNA was isolated from peripheral leukocytes (105 patients and 123 controls), cultured fibro-
blasts (7 patients and 1 control) and both peripheral leukocytes and cultured fibroblasts (17 patients and 1 control) by standard procedures. PCR and RFLP of patient and control DNA samples were performed as described previously [6]. When a positive result was found, the fragments of mtDNA were sequenced as reported before [7] and sequences were compared with the revised Cambridge sequence of the human mitochondrial genome [13]. In order to verify if the PCR product was an amplification of mtDNA genes or nuclear pseudogenes, we also analyzed total cellular DNA isolated from ρ0 cells. DNA analyses were performed blind to the diagnosis, and subject identities were known only after the results had been completed.

Results and Discussion

Only one AD patient (P1) showed a homoplasmic mtDNA modification at nucleotides 3337–3340 by PCR-RFLP analysis. He was 54 years old, and the onset of disease occurred at 53 years. Although the MMSE score was in the normal range (29) at the first visit, neuropsychological assessment confirmed a deterioration in memory and language, and the patient was classified as mildly demented using CDR (1); there was no family history reported. Additionally, an unexpected pattern at agarose gel electrophoresis occurred in another sample: fragments presenting lower molecular weight (141 bp + 69 bp) than the wild-type (210 bp + 79 bp) or mutant (289 bp) bands, together with the 79-bp band, were found in a 68-year-old male AD patient (P2) who scored 22 and 1 on the MMSE and CDR, respectively. His age at disease onset was 65 years, and he had no family history. Sequence analysis confirmed the PCR-RFLP result. P1 presented a known missense transition T-C at nucleotide 3338 of the mtDNA ND1 gene, which promotes the change of valine to alanine in the peptide chain (fig. 1). This change is considered a harmless polymorphism, based on studies of amino acid residue substitutions [14], and was found through sequence analysis in 1 patient with hypertrophic cardiomyopathy [15, 16], 1 with PD [4] and 1 multiple sclerosis control subject [5]. This is a highly conserved nucleotide among the hominoid primates (data not shown), as well as nucleotides 3339 and 3340, which do not occur with nucleotide 3337. Additionally, P1 presented another known T-C transition at nucleotide 3197 of the 16S rRNA mtDNA gene (fig. 1), which had previously been described [17] in a patient with ischemic colitis and in AD, PD, AD + PD patients and Caucasian controls [18] as a polymorphism, also reported as associated with the haplogroup U5, present in the European populations [19], and very weakly conserved among hominoid primates (data not shown). P2 presented a normal sequence at nucleotides 3337–3340 (GTAC), but we have found a novel homoplasmic alteration at nucleotide 3199 of the 16S rRNA mtDNA gene (fig. 1), a T-C transition, originating a cleavage site (GTAC sequence) recognized by Csp 6I endonuclease and originating altogether three bands with 141, 79 and 69 bp, after electrophoresis. This is a very weakly conserved nucleotide in hominoid primates since there is a C in the genus Pan (chimpanzee and bonobo), a T in Gorilla gorilla and Homo sapiens and a nucleotide deletion or a C in Pongo pygmaeus (data not shown).

To our knowledge, this nucleotide change is reported here for the first time, and it seems unlikely that it is a causative mutation. We have screened all the other patients and the 125 controls for the presence of this new variant, but no other positive samples were found. Additionally, there was no amplification of the total cellular DNA isolated from ρ0 cells, confirming that we were analyzing mtDNA and not nuclear pseudogenes.

Conclusion

mtDNA ND1 nucleotides 3337–3340 seem unlikely to be a primary risk factor for AD in the population under study (central region of Portugal), which is in agreement with the current literature, but does not rule out the possible contribution of ND1, 16S rRNA, or any other mtDNA gene to the pathogenesis of AD. In fact, it is possible that distinct combinations of nonmutated electron transport chain components do not function identically; being so, nonpathogenic mtDNA variations could contribute to AD risk, while at the same time explaining why associations between mtDNA polymorphism and AD are difficult to establish [20].

Acknowledgements

We would like to acknowledge Prof. A. Münich, Dr. P. Rustin and Dr. A. Rötig for providing ρ0 cell DNA. We thank the Histocompatibility Centre of Coimbra for providing the facilities for sequence analysis. This work was partially supported by a scholarship from the Fundação para a Ciência e Tecnologia – Fundo Social Europeu, III Quadro Comunitário de apoio (PRAXIS XXI/BD/4049/94) and by a scholarship (prized project on Brain Aging, Alzheimer Disease and Other Dementia) from the Sociedade Portuguesa de Neurociências (sponsored by Pfizer laboratories).
References


